font size
Sign in

PRIVACY:

Why GINA Can Be Problematic in the Workplace

Podcast: February 8, 2010


A policy approved by The University of Akron last summer – before the Genetic Information Non-Discrimination Act took effect – required criminal background checks for nearly all prospective employees, including the possible collection of DNA samples. The policy was retracted following a public outcry, but it left uncertainty about how GINA applies to employers. Shawneequa Callier, a post doctoral fellow at the Center for Genetic Research, Ethics, and Law in the Bioethics Department at Case Western Reserve University co-authored an essay on the controversy in the latest Hastings Center Report. We spoke to Callier about the UA case, how it played out against the implementation of GINA and why enforcement of the new law can be problematic. 
Read More
Todays Stories
VIDEO The Life Sciences in the News

Lancet Retracts Autism Study
View Video

Podcast With Healthcare Reform Uncertain, BIO's Policy Fights Remain


Jim Greenwood, president and CEO of the Biotechnology Industry Organization, discusses the uncertainty surrounding healthcare reform, what it means for such issues as follow-on biologics, and what the industry’s policy agenda looks like for 2010.

By the numbers First Biotech IPO of 2010 Debuts


Ironwood Pharmaceuticals became the first biotech to go public in 2010. The company had hoped to raise upwards of $270 million through the sale of 16.7 million shares in the range of $14 to $16 a share. In the end, however, it priced its shares at $11.25 raising just $187.5 million. While this was a significant price cut, it managed to get its IPO done.